Indiplon: The development of a new hypnotic

Expert Opinion on Investigational Drugs

Volumn 14, Issue 10, 2005, Pages 1269-1276

  Neubauer, David N ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

1 selective; GABAA receptors; Hypnotic; Indiplon; Insomnia; Modified release; Nonbenzodiazepine; Sleep disorders

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; CL 285489; ESTAZOLAM; ESZOPICLONE; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC AGENT; INDIPLON; LOPRAZOLAM; LORMETAZEPAM; MELATONIN RECEPTOR; NITRAZEPAM; PLACEBO; QUETIAPINE; RAMELTEON; SHORT ACTING DRUG; TEMAZEPAM; TRAZODONE; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; ZOPICLONE;

AGE; ALPHA CHAIN; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; INSOMNIA; NONHUMAN; PHARMACODYNAMICS; PRACTICE GUIDELINE; RESPIRATION DEPRESSION; SEDATION; SEX DIFFERENCE; SLEEP DISORDER; STRUCTURE ANALYSIS; TABLET FORMULATION;

ANIMALS; BENZODIAZEPINES; DRUGS, INVESTIGATIONAL; HUMANS; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS; THIOPHENES;

EID: 27144505803     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.10.1269     Document Type: Article

References (27)

1. NEUBAURE DN: Understanding Sleeplessness: Perspectives on Insomnia. Johns Hopkins University Press, Baltimore (2003).
2. OHAYON MM, ROTH T: Place of chronic insomnia in the course of depressive and anxiety disorders. J. Psychiatr. Res. (2003) 37:9-15.
3. FORD DE, KAMEROW DB: Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA (1989) 262:1479-184.
4. MENDELSON WB, ROTH T, CASELLA J et al.: The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Med. Rev. (2004) 8:7-17.
5. ADIS INTERNATIONAL LIMITED: Indiplon. Indiplon modified-release, indiplon MR, NBI 34060, NBI 34060 modified-release, NBI 34060 MR. Drugs R&D (2002) 3:197-199.
6. FOSTER AC, PELLEYMOUNTER MA, CULLEN MJ et al.: In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J. Pharmacol. Exp. Ther. (2004) 311(2):547-559.
7. A receptor. J. Pharmacol. Exp. Ther. (2004) 311(2):537-546.
8. A receptors. Society for Neuroscience 2004 Abstract Viewer/Itinery Planner. Washington DC USA. (2004) (Program No. 160.7).
9. JOCHELSON P, CHEN TK, FARBER R, CAMPBELL B: Lack of pharmacological and pharmacokinetic tolerance following repeat dosing of indiplon (NBI-34060). Sleep (2003) 26:A85-A86 (Abstract supplement).
10. FISHER D, YUAN Z, JIN L et al.: In vitro metabolism of NBI-34060 (indiplon) and its potential to inhibit P450 enzymes. Drug Metab. Rev. (2002) 34(Suppl. 1):171.
11. BERKOWITZ DV, SCHARF MB, JOCHELSON P et al.: The co-administration of indiplon (NBI-34060) and alcohol lacks pharmacokinetic and pharmacodynamic interaction. Sleep (2003) 26:A81 (Abstract supplement).
12. ROGOWSKI R, GARBER M, BOZIGIAN H, JOCHELSON P, FARBER R, CAMPBELL B: NBI-34060 (a non-benzodiazepine sedative-hypnotic): lack of a pharmacokinetic gender effect. Sleep (2002) 25:A415 (Abstract supplement).
13. JOCHELSON P, ROGOWSKI R, BURKE J et al.: The pharmacokinetics of the non-benzodiazepine sedative-hypnotic, NBI-34060 in elderly subjects. Sleep (2002) 25:A415-A416 (Abstract supplement).
14. ROTH T, WALSH JK, ROGOWSKI R, FARBER R, BURKE J, JOCHELSON P: Efficacy and tolerability of indiplon (NBI-34060) solution in healthy adults in a model on transient insomnia. Sleep (2003) 26:A87 (Abstract supplement).
15. SCHARF MB, ROTH T, ROSENBERG R, LANKKORD DA, ALEXANDER T: Efficacy and tolerability of indiplon IR in the treatment of transient insomnia. Sleep (2004) 27:A267 (Abstract supplement).
16. WALSH JK, ROSENBERG R, ROTH T, LANKFORD DA, JOCHELSON P: Treatment of primary insomnia for five weeks with indiplon-IR. Sleep (2004) 27:A259 (Abstract supplement).
17. SCHARF MB, ROSENBERG R, COHN M et al.: Safety and efficacy of immediate release indiplon (NBI-34060) in elderly patients with insomnia. Sleep (2003) 26:A85 (Abstract supplement).
18. WALSH JK, ROTH T, MOSCOVITCH A, FARBER R, JOCHELSON P: Efficacy and tolerability of indiplon-IR in elderly patients with primary insomnia. Sleep (2005) 28:A229 (Abstract supplement).
19. SCHARF MB, BLACK J, HULL S et al.: Long term efficacy and tolerability of indiplon-IR in the treatment of chronic insomnia: results of a double-blind, placebo-controlled 3-month study. Sleep (2005) 28:A229 (Abstract supplement).
20. ROTH T, ZAMMIT G, SCHARF MB, BOYD M, JOCHELSON P: Efficacy and safety of indiplon-IR in adults with chronic insomnia characterized by prolonged nighttime awakenings with difficulty returning to sleep. Sleep (2005) 28:A229 (Abstract supplement).
21. JOCHELSON P, BOZIGIAN H, GARBER M et al.: The activity of modified release indiplon (NBI-34060) in a transient nighttime venipuncture model. Sleep (2003) 26:A84 (Abstract supplement).
22. JOCHELSON P, SCHARF M, ROTH T, WALSH JK, GARBER M: Efficacy of indiplon in inducing and maintaining sleep in patients with chronic sleep maintenance insomnia. Sleep (2004) 27:A262 (Abstract supplement).
23. WALSH JK, LANKFORD DD, KRYSTAL A et al.: Efficacy and tolerability of four doses of indiplon (NBI-34060) modified-release in elderly patients with sleep maintenance insomnia. Sleep (2003) 26:A78 (Abstract supplement).
24. LANKFORD J, LYDIARD R, WALSH JK, SEIDAN D, JOCHELSON P: Efficacy and tolerability of indiplon-MR in elderly patients with chronic insomnia: results of a double-blind, placebo-controlled, 2-week trial. Sleep (2005) 28:A230 (Abstract supplement).
25. 2 challenge model. Sleep (2004) 27:A261 (Abstract supplement).
26. HULL S, FPGARTY C, VINCE B, CHEDIAK AD, JOCHELSON P, GATELY N: Safety of indiplon-MR in patients with mild-to-moderate COPD. Sleep (2004) 27:A261 (Abstract supplement).
27. GARBER M, BURKE J, FARBER R, JOCHELSON P, CAMPBELL B: Residual effects of middle of the night dosing: a placebo-controlled crossover study of indiplon-IR, zolpidem, and zolpiclone in healthy volunteers. Sleep (2004) 27:A260 (Abstract supplement).